Use of drugs with Pharmacogenomics (PGx)-Based Dosing Guidelines in a
Danish Cohort of Persons with Chronic Kidney Disease, Both on Dialysis
and Not on Dialysis: Perspectives for Prescribing Optimization
Aim: The objective of this registry study is to assess the
utilization of PGx drugs among patients with CKD Methods: This
study was a retrospective study of patients affiliated to the Department
of Nephrology, Aalborg University Hospital, Denmark during 2021.
Patients diagnosed with CKD were divided into CKD without dialysis and
CKD with dialysis. PGx prescription drugs were retrieved from the
Patient Administration System. Actionable dosing guidelines (AG) for
specific drug-gene pairs for CYP2D6, CYP2C9, CYP2C19 and SLCO1B1were
retrieved from the PharmGKB homepage. Results: Out of 1241
individuals, 25.5% were on dialysis. The median number of medications
for each patient was 9 within the non-dialysis group, and 16 within the
dialysis group. Thirty-one distinct PGx drugs were prescribed.
Altogether, 76.0% (943 individuals) were prescribed at least 1 PGx
drugs and the prevalence of prescriptions of PGx drugs was higher the
dialysis group compared to the non-dialysis group. The most frequently
prescribed drugs with AG were metoprolol, pantoprazole, atorvastatin,
simvastatin, warfarin. Conclusion: This study demonstrated that
a substantial proportion of patients with CKD are exposed to drugs or
drug combinations for which there exists actionable dosing guidelines
related to PGx of CYP2D6, CYP2C19, CYP2C9, and SLCO1B1.